SF-5290 would amend Minnesota’s individual income tax and corporate franchise tax laws. It would require taxpayers to add back certain direct-to-consumer pharmaceutical marketing expenses when calculating Minnesota taxable income, even if they deducted those expenses under federal tax law. The bill does not state a goal beyond requiring this tax adjustment; it is introduced and has not become law.
No estimate of state revenue or administration costs is provided. No publicly available information.
Bills on related subjects, starting with Minnesota.
Lawmakers would require addbacks of qualifying direct-to-consumer pharma marketing deductions for Minnesota income and corporate taxes starting in 2027.
Status
Introduction and first reading, referred to Taxes
Senate bill would apply Medicare price rules to Minnesota drug sales, with a price cap and reimbursement rules starting January 1, 2027.
Status
Referred to Health and Human Services
A bill would cap prices for Medicare-negotiated drugs in Minnesota and require reimbursements at the higher of the cap or NADAC, with withdrawal penalties; effective January 1, 2027.
Status
Authors added Berg; Kozlowski; Pursell; Jordan; Kraft; Johnson, P.; Freiberg; Virnig; Liebling; Gottfried; Youakim; Greenman; Feist; and Falconer
A bill would award a one-time rebate to eligible vehicle owners and switch registration tax calculations to MSRP-based schedules starting Jan 1, 2027.
Status
Introduction and first reading, referred to Transportation Finance and Policy